THYROID EYE DISEASE
Clinical trials for THYROID EYE DISEASE explained in plain language.
Never miss a new study
Get alerted when new THYROID EYE DISEASE trials appear
Sign up with your email to follow new studies for THYROID EYE DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug IBI3031 enters first human trial for thyroid eye disease
Disease control Not yet recruitingThis early-stage trial tests the safety and tolerability of a new drug called IBI3031 in 66 people with moderate-to-severe active thyroid eye disease. Participants will receive either the drug or a placebo by injection or infusion. The study aims to find the right dose and check …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug NTB003 aims to reduce bulging eyes in thyroid disease
Disease control Not yet recruitingThis early-stage trial tests a new drug called NTB003 in 74 people with thyroid eye disease, a condition that can cause bulging eyes and inflammation. Participants receive injections of NTB003 or a placebo every 4 weeks. The study measures whether the drug reduces eye bulging and…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could fewer infusions tame thyroid eye disease?
Disease control Not yet recruitingThis study compares a shortened 4-infusion course of the drug Teprotumumab (Tepezza) against the standard 8-infusion course for people with active thyroid eye disease. Only patients who show a good early response will be eligible for the shorter regimen. The goal is to see if few…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE4 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug aims to reduce bulging eyes in thyroid disease
Disease control Not yet recruitingThis study tests a new drug called teprotumumab N01 for active thyroid eye disease, which causes eye bulging and discomfort. About 92 adults will receive either the new drug or standard steroid treatment. The main goal is to see if the new drug better reduces eye bulging.
Matched conditions: THYROID EYE DISEASE
Phase: PHASE4 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Your phone camera could soon spot eye disorders
Diagnosis Not yet recruitingThis study will check if an AI system can accurately measure eye movements from smartphone videos. About 1,000 adults with suspected eye movement issues will record a short video while following a moving target. The AI's measurements will be compared to expert ratings to see if i…
Matched conditions: THYROID EYE DISEASE
Sponsor: THYROSCOPE INC. • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC